What Are Hemostatic Agents and How Do They Work?

Hemostatic agents are materials applied to a wound or administered systemically to speed up, strengthen, or initiate blood clotting. They range from simple gauze impregnated with minerals to sophisticated biological products that replicate the body’s own clotting chemistry. Some work passively, absorbing fluid and concentrating the blood’s natural clotting ingredients at the wound surface. Others actively supply clotting proteins like thrombin or fibrinogen, effectively jumpstarting the process from the outside. The field has expanded dramatically over the past few decades, and the variety of products now available reflects real differences in mechanism, setting, and intended patient.

What Happens When You Bleed Normally

To understand how hemostatic agents work, it helps to know the basics of what your body already does. When a blood vessel is damaged, the body launches a rapid cascade of enzymatic reactions. Proteins in the blood called serine proteases activate one another in a chain, ultimately converting a dissolved protein called fibrinogen into fibrin, an insoluble mesh that traps blood cells and forms the structural backbone of a clot. Platelets simultaneously stick to the damaged vessel wall and to one another, reinforcing the fibrin scaffold. This is normal hemostasis, and it works well for most everyday cuts and scrapes.¹

The problem arises when the injury is too severe, the blood vessels too large, or the patient’s own clotting system is compromised by medication, disease, or hypothermia. In those situations, the body cannot close the leak on its own quickly enough, and hemostatic agents step in to tip the balance.

Passive Agents That Concentrate Clotting Factors Mechanically

The simplest hemostatic agents do not add any biological clotting ingredients. Instead, they create a physical environment that helps the body’s own system work faster. These are sometimes called passive or mechanical hemostats, and they include products made from oxidized cellulose, gelatin, collagen, and certain polysaccharide powders.

Oxidized cellulose, one of the oldest topical hemostats still in wide use, works primarily by absorbing fluid. As it swells with blood, it concentrates platelets, red blood cells, and clotting proteins at the wound surface, creating a high local concentration that accelerates natural clot formation.² The low pH of the material also has a mild caustic effect on tissue, which contributes to sealing small vessels. Gelatin-based products function similarly, forming a physical matrix that supports platelet aggregation. These agents are typically biodegradable and can be left in the wound, where the body breaks them down over days to weeks.

A newer variation on this theme is the modified absorbable polymer, sold under brand names like PerClot. These granules rapidly absorb water from blood, forming a gelled adhesive matrix that acts as a mechanical barrier. Platelets, red blood cells, and coagulation proteins accumulate around this scaffold, and the normal clotting cascade proceeds on top of it.³ The key point is that these agents do not supply any clotting proteins themselves. They rely entirely on the patient’s blood having enough of its own.

Active Agents That Supply Clotting Proteins

When passive concentration is not enough, active hemostatic agents bring their own clotting ingredients to the party. The most prominent example is fibrin sealant, a two-component product that contains both fibrinogen and thrombin. When the two are mixed at the wound site, the thrombin converts fibrinogen into insoluble fibrin, replicating the final steps of the clotting cascade without depending on the patient’s own coagulation system.⁴ This makes fibrin sealants particularly valuable for patients whose clotting is impaired, whether from disease, medications, or the physiological derangement that accompanies major trauma.

Thrombin alone is also available as a topical agent, usually combined with a gelatin or collagen carrier. So-called flowable hemostats use a gelatin-thrombin combination that can be injected or squeezed into irregularly shaped wounds and deep crevices that flat pads cannot reach. In animal studies of severe liver injuries, a thrombin-gelatin flowable product achieved hemostasis more effectively, reduced blood loss, and improved survival compared to standard wound packing.⁵ The ability to conform to complex wound geometry gives flowable agents an edge in surgeries involving the liver, spleen, and other organs with uneven surfaces.

Mineral-Based and Polysaccharide Agents

Some hemostatic agents rely on inorganic minerals. Kaolin and zeolite, both naturally occurring aluminosilicate minerals, promote clotting through a mechanism distinct from the passive absorption described above. Kaolin activates factor XII, an early protein in the clotting cascade, while zeolite concentrates later factors on its surface in a way that boosts thrombin generation.⁶ Combining the two creates a synergistic effect, accelerating clotting at both ends of the cascade simultaneously. Kaolin-impregnated gauze is now one of the most common hemostatic dressings in military and civilian trauma care.

On the biological side, chitosan, a polymer derived from the shells of crustaceans like shrimp and crabs, takes yet another approach. Chitosan carries a positive electrical charge, which attracts negatively charged red blood cells and platelets directly to its surface. This contact-based mechanism works independently of the body’s coagulation cascade, meaning it can promote clotting even in patients whose clotting pathways are suppressed.⁷ Chitosan-based products have found roles in both military trauma kits and dental surgery, where their independence from host coagulation is a practical advantage.

Choosing the Right Agent in Surgery

With so many products available, surgeons make decisions based on the type, location, and severity of bleeding. A large review of topical hemostatic agents in surgery found that inactive matrix agents are generally best suited for diffuse, low-grade venous oozing, while biologically active agents that supply thrombin or fibrinogen are more appropriate for brisk arterial bleeding or patients whose blood does not clot normally.⁸ The anatomy matters too. Pelvic surgery, neurosurgery, and liver resection each present different challenges in terms of wound shape, accessibility, and the fragility of surrounding tissue.⁹

In practice, many surgical teams keep several types on hand. A surgeon dealing with minor ooze from a raw tissue surface might reach for an oxidized cellulose pad, while switching to a thrombin-gelatin flowable if a deeper vessel starts bleeding in a tight space. Fibrin sealant might come out for a patient with known coagulopathy or when the bleeding is diffuse and hard to localize. The agents are not interchangeable, and using the wrong class for the situation can waste time, money, and product without controlling the bleed.

Trauma and Prehospital Use

Outside the operating room, hemostatic agents face harsher conditions. A soldier or paramedic dealing with a major wound cannot choose from a cabinet of options, apply the product under surgical lighting, or wait several minutes for it to take effect. The product needs to work fast, tolerate imperfect application, and hold up under conditions like hypothermia and acidosis that impair normal clotting.

Kaolin-impregnated Combat Gauze has become a standard in this arena. In a study simulating severe coagulopathic conditions, Combat Gauze achieved hemostasis on the first application 93% of the time, compared to a 0% success rate for standard gauze. On a second application, both reached 100%, but the kaolin product consistently reduced clotting time compared to the control.¹⁰ Head-to-head comparisons with chitosan-based alternatives have reinforced this advantage. In one study, all subjects treated with Combat Gauze achieved initial hemostasis, compared to 70% of those treated with Celox Rapid, a chitosan product. Over a one-hour observation window, the kaolin gauze maintained hemostasis in all subjects while the chitosan product dropped to a 60% success rate.¹¹

These numbers do not mean chitosan products are ineffective. Different products suit different wound types, and chitosan’s ability to work independently of the clotting cascade is valuable when patients are on blood thinners or in deep hypothermia. But for the sheer reliability of first-application success in traumatic hemorrhage, kaolin gauze has accumulated the strongest evidence base.

Hemostatic Agents for Patients on Blood Thinners

One of the more practical questions about hemostatic agents is whether they work in people taking anticoagulant medications like warfarin, heparin, or the newer direct oral anticoagulants. These drugs deliberately impair the clotting cascade, which is exactly what hemostatic agents need to work with or work around.

The answer depends on the agent’s mechanism. Active agents like fibrin sealant, which supply their own thrombin and fibrinogen, can bypass the patient’s impaired cascade to some extent. Chitosan, as mentioned, works by direct contact with blood cells rather than through the clotting cascade, giving it an independent pathway. And kaolin-coated dressings have shown promise even in anticoagulated patients. In laboratory testing, adding kaolin-coated material to blood from patients on various anticoagulants significantly improved the time to initial clot formation, suggesting that the mineral’s activation of factor XII can partially overcome the drug’s effects.¹²

In dental surgery, which frequently involves patients on blood thinners, chitosan-based dressings have been shown to significantly shorten bleeding time after tooth extractions in patients on oral anticoagulant therapy.¹³ Platelet-rich fibrin, a biologically derived material prepared from the patient’s own blood, has also been studied in anticoagulated dental patients. A systematic review found that all included studies showed sufficient hemostasis when platelet-rich fibrin was used, though the evidence was too varied in design to combine into a single statistical analysis.¹⁴

Systemic Hemostatic Agents

Not all hemostatic agents are applied directly to wounds. In emergency medicine and surgery, systemically administered products can bolster the blood’s clotting ability from the inside. Prothrombin complex concentrate provides a cocktail of clotting factors that are depleted by anticoagulant drugs like warfarin, effectively reversing the drug’s effect. Recombinant factor VIIa is another option, a genetically engineered version of a single clotting factor that can kickstart thrombin generation.

Both are used for uncontrolled bleeding during cardiac surgery and in trauma patients on anticoagulants.¹⁵ In animal models comparing the two, prothrombin complex concentrate fully normalized clotting times and blood loss in a sustained anticoagulation scenario, while recombinant factor VIIa corrected some laboratory values but did not significantly reduce actual blood loss under the same conditions.¹⁶ The practical lesson is that these agents are not interchangeable, and the choice depends on the clinical scenario, the cause of the coagulopathy, and what endpoints matter most.

Risks and Complications

Hemostatic agents are not without downsides. The most commonly discussed risk of topical agents is the potential for foreign body reactions. If a product is left in the body after surgery and does not degrade cleanly, it can trigger chronic inflammation, infection, or granuloma formation, a lump of immune tissue that can mimic a tumor on imaging and sometimes requires surgical removal.¹⁷ This is particularly relevant for absorbable products like oxidized cellulose and gelatin sponges, which are designed to be left in place but can occasionally cause problems when they do not dissolve as expected.

Thrombin-containing products carry a theoretical risk of promoting clots where you do not want them, though this is rare with topical application. The risk rises with systemic agents like prothrombin complex concentrate, where the whole point is to make the blood more prone to clotting. Surgeons and emergency physicians weigh the life-threatening bleeding against the clotting risk on a case-by-case basis.

Early kaolin- and zeolite-based products caused a separate problem: exothermic reactions. First-generation granular products generated heat when they contacted blood, sometimes enough to burn tissue. Modern impregnated gauze products largely solved this by binding the mineral to a fabric carrier, which dissipates the heat and makes the product much safer to use.

Hemostatic Agents in Children

Pediatric patients present a specific concern because their smaller blood volumes make even modest bleeding more dangerous, and their tissues are more delicate. A study comparing a fibrin sealant to an oxidized cellulose hemostat in children found that the fibrin product achieved hemostasis within four minutes in about 80% of cases, versus 65% for the cellulose product. By seven minutes, the fibrin group had reached 100% success. Treatment failure, meaning hemostasis was never achieved, occurred in only 5% of the fibrin group compared to 25% of the control group, and re-bleeding rates were lower as well.¹⁸ No deaths or blood clot complications occurred in either group, which is reassuring given the concern about using active clotting agents in small patients.

How the Field Got Here

The use of hemostatic agents stretches back over a century. Fibrin sealants, gelatin-based products, oxidized cellulose, and collagen products are the four major classes that have evolved over that time. Three of those classes have remained relatively unchanged since their development, with improvements mostly in format and preparation rather than fundamental mechanism. Fibrin sealants are the exception, having undergone steady evolution and holding the most promise for future adaptation.¹⁹ Neurosurgery, a field where bleeding control is critical and the margin for error is minimal, has been an important driver of hemostatic innovation since the early 1800s, pushing the development of mechanical, chemical, and thermal approaches in roughly that chronological order.²⁰

What Is Coming Next

The next generation of hemostatic agents is moving toward “smart” materials that respond to their environment. Researchers are developing self-healing colloidal hydrogels, flowable matrices made of gelatin sub-microparticles that self-assemble into an integrated gel network at the wound site. One such product demonstrated a healing efficiency exceeding 95%, meaning the gel could reform rapidly after being disrupted, and has already progressed from laboratory testing to human clinical trials.²¹

Biomimetic strategies are also gaining traction. One approach uses a recombinant fusion protein that combines human-derived collagen with a self-assembling peptide. Under normal body conditions, this engineered protein spontaneously forms a three-dimensional nanofiber network that mimics the body’s own tissue scaffolding, providing a surface for cells to adhere to and promoting both clotting and wound healing simultaneously. Beyond biomimicry, researchers are exploring materials that respond to specific triggers: light, temperature changes, moisture, or even electric fields. These “intelligent responsive” hemostatic materials aim to activate precisely at bleeding sites and stop acting once the wound is sealed.²²

Shelf stability is another practical frontier. Many current hemostatic agents require refrigeration or have limited shelf lives, which complicates storage in remote or resource-limited settings. Recent work on tranexamic acid gauze showed that the product maintained its hemostatic effectiveness without significant drug degradation over six months of stability testing at various temperatures.²³ For military medics, wilderness first responders, and clinics in tropical climates, products that hold up without a cold chain could make a real difference in outcomes.